| All Releases |
 |
Eurand to Present at Barclays Capital Global Healthcare Conference
Mar 10, 2010
|
9.9 KB |
|
| |
PHILADELPHIA, PA, Mar 10, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that it is scheduled to present at the upcoming Barclays Capital 2010 Global Healthcare Conference. Gearoid Faherty, Eurand's Chairman and Chief Executive Officer, will be presenting.
...
|
|
Eurand Reports Recent Developments and Fourth Quarter and Full-Year 2009 Financial Results
Mar 4, 2010
|
26.2 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Mar 04, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX)
Recent Developments:
-- Fourth quarter 2009 revenues were EUR 30.3 million ($43.4 million), up 18%, or 28% in constant currency, from the fourth quarter of 2008.
-- Full-year revenues in 2009 grew to a record EUR 120.6 million ($1...
|
|
Eurand to Present at Cowen Health Care Conference
Feb 24, 2010
|
9.9 KB |
|
| |
PHILADELPHIA, PA, Feb 24, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that it is scheduled to present at the upcoming Cowen Health Care Conference. John Fraher, Eurand's Chief Commercial Officer, will be presenting.
Event: Cowen Health Care Conference
Dat...
|
|
Eurand Issued U.S. Patent for ZENPEP(R) (pancrelipase) Delayed-Release Capsules
Feb 16, 2010
|
11.4 KB |
|
| |
PHILADELPHIA, PA, Feb 16, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today the grant of U.S. Patent No. 7,658,918, titled "STABLE DIGESTIVE ENZYME COMPOSITIONS," by the United States Patent and Trademark Office (USPTO). The patent will provide Eurand with coverage un...
|
|
Eurand Announces Conference Call on Fourth Quarter and Full-Year 2009 Financial Results
Feb 4, 2010
|
11.1 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Feb 04, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, will host a conference call on Thursday, March 4, 2010 at 8:30 a.m. ET to discuss its fourth quarter and full-year 2009 financial results. The conference call will be hosted by Gearoid Faherty, Chai...
|
|
Eurand to Present at Deutsche Bank Securities Small- and Mid-Cap Conference
Jan 27, 2010
|
10.1 KB |
|
| |
PHILADELPHIA, PA, Jan 27, 2010 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, announced today that it is scheduled to present at the upcoming Deutsche Bank Securities Small- and Mid-Cap Conference. Presenting will be Bill Newbould, Eurand's Vice President, Investor Relations.
Eve...
|
|
Eurand Launches ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules
Nov 30, 2009
|
20.1 KB |
|
| |
PHILADELPHIA, PA, Nov 30, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced the commercial availability of ZENPEP(TM) (pancrelipase) Delayed-Release Capsules, a pancreatic enzyme product (PEP) indicated for the treatment of exocrine pancreatic insufficiency (EPI) due ...
|
|
Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients With Exocrine Pancreatic Insufficiency
Nov 13, 2009
|
15.8 KB |
|
| |
PHILADELPHIA, PA, Nov 13, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced data from a Phase II/III clinical study demonstrating that ZENPEP(TM) (pancrelipase) Delayed-Release Capsules significantly improves fat absorption in patients with exocrine pancreatic insuffi...
|
|
Eurand Reports Key Achievements and Strong Revenue Growth for Third Quarter 2009
Nov 5, 2009
|
25.7 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Nov 05, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX)
Key Achievements:
-- Received U.S. Food and Drug Administration (FDA) approval for lead
proprietary product ZENPEP(TM) (pancrelipase) Delayed-Release Capsules, a
pancreatic enzyme product (PEP) for the treatment of exocri...
|
|
Eurand to Participate in Upcoming Investor Conferences
Oct 28, 2009
|
10.7 KB |
|
| |
PHILADELPHIA, PA, Oct 28, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, is scheduled to participate in the following upcoming investor conferences:
Event: Barclays Capital Healthcare Small Cap One on One Day
Date: Tuesday, November 10, 2009
Time: 7:30 a.m. to 4:00...
|
|
Eurand Completes Public Offering, Including Exercise of the Underwriters' Over-Allotment Option, for Total Net Proceeds of Approximately $103.9 Million
Oct 28, 2009
|
13.0 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Oct 28, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced the closing of its previously reported offering of 9,775,000 ordinary shares at the public offering price of $11.25 per share. The shares offered include the 1,275,000 shares underly...
|
|
Eurand Announces Pricing of Offering of Ordinary Shares
Oct 22, 2009
|
12.9 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Oct 22, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced the pricing of its previously disclosed public offering of 8,500,000 ordinary shares at an initial price to the public of $11.25 per share. The shares are being offered through an un...
|
|
Eurand Announces Proposed Public Offering of Ordinary Shares
Oct 15, 2009
|
12.1 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Oct 15, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced the proposed sale of 8,500,000 ordinary shares in an underwritten public offering, subject to market and other conditions.
Of the 8,500,000 shares being offered, 2,000,000 are to...
|
|
Eurand Announces Conference Call on Third Quarter 2009 Financial Results
Oct 5, 2009
|
11.0 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Oct 05, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, will host a conference call on Thursday, November ...
|
|
Eurand Announces Filing of F-3 Registration Statement
Sep 28, 2009
|
11.6 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Sep 28, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, today announced that it filed a registration statement on Form F-3 for a proposed o...
|
|
Eurand to Present at UBS Global Life Sciences Conference
Sep 16, 2009
|
9.9 KB |
|
| |
PHILADELPHIA, PA, Sep 16, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that John Fraher, Chief Commercial Officer, is scheduled to present at the fo...
|
|
Eurand Granted FDA Approval for ZENPEP(TM)
Aug 28, 2009
|
20.0 KB |
|
| |
PHILADELPHIA, PA, Aug 28, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company, today announced U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for ZENPEP(TM) (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) ...
|
|
Eurand to Participate in Upcoming Investor Conferences
Aug 19, 2009
|
10.8 KB |
|
| |
PHILADELPHIA, PA, Aug 19, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, is scheduled to participate in the following upcoming investor conferences:
Event: FT...
|
|
Eurand Reports Recent Developments and Second Quarter 2009 Financial Results
Aug 6, 2009
|
24.5 KB |
|
| |
AMSTERDAM, THE NETHERLANDS, Aug 06, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX)
Recent Developments:
-- Second quarter 2009 revenues grew 31%, or 19% at constant currency
rates, to EUR 30.6 million ($42.8 million U.S.) compared with the same
period in 2008
-- U.S. Food and Drug Administration (FDA)...
|
|
Eurand Successfully Completes Registration Procedure for Paracetamol ODT 250 and 500 mg in the European Union
Jul 20, 2009
|
12.2 KB |
|
| |
MILAN, ITALY, Jul 20, 2009 (MARKETWIRE via COMTEX News Network) -- Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that the Dutch Medicines Evaluation Board (MEB) informed the Company that the Dec...
|
|
|
